{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:07:38Z","timestamp":1791940058786,"version":"4.3.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00616","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T05:17:16Z","timestamp":1544678236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK"],"prefix":"10.3389","volume":"8","author":[{"given":"Shinya","family":"Uozumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"B1","volume-title":"World Cancer Report","author":"Stewart","year":"2003"},{"key":"B2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"B3","volume-title":"Cancer Information Service, National Cancer Center","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"B6","first-page":"Abstract817","article-title":"The presence and intensity of the cetuximab-induced acne like rash predicts increased survival in studies across multiple malignancies","volume":"21","author":"Saltz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3892\/or_00000319","article-title":"Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor inhibitor cetuximab: A single institution retrospective analysis","volume":"21","author":"Orditura","year":"2009","journal-title":"Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1470-2045(10)70278-3","article-title":"First cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study","volume":"12","author":"Gatzemeier","year":"2011","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetixumab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in inrinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinoteacn, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.oraloncology.2012.09.003","article-title":"Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent\/metastatic head and neck cancer patients","volume":"49","author":"Jimenez","year":"2013","journal-title":"Oral Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.ijrobp.2016.03.011","article-title":"Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the RTOG Experience","volume":"95","author":"Bar-Ad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: observation from 933 patients enrolled in North Central Cancer Treatment Group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacoutur","year":"2011","journal-title":"Support Care Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35193","DOI":"10.18632\/oncotarget.17060","article-title":"Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash","volume":"8","author":"Hichert","year":"2017","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.6021","article-title":"Platinum \u2013based chemotherapy(CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer(R\/M-SCCHN):5-year follow-up data for the extreme trial","volume":"32","author":"Vermorken","year":"2014","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12788\/jcso.0193","article-title":"Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review","volume":"14","author":"Brown","year":"2016","journal-title":"J Communitiy Support Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/1078-0432.CCR-09-1928","article-title":"Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment","volume":"16","author":"Klinghammer","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T05:17:17Z","timestamp":1544678237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":20,"alternative-id":["10.3389\/fonc.2018.00616"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00616","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"article-number":"616"}}